Posttraumatic osteoarthritis (PTOA) is a special form of osteoarthritis (OA), developing after joint injuries. Except for some minor clinical differences, no biologic marker has yet been identified to distinguish idiopathic OA (IOA) from PTOA. In this study, we investigated the expression of the stress-responsive cytokine growth differentiation factor 15 (GDF-15) in clinical samples from the Ulm OA study cohort and in a human ex vivo cartilage trauma model. GDF-15 levels were significantly higher in synovial fluid of PTOA patients as compared to IOA patients. We confirmed that fibroblast-like synoviocytes secreted GDF-15 after stimulation with medium of ex vivo-traumatized cartilage. Moreover, GDF-15 and its receptor, GFRAL, were elevated in highly degenerated OA cartilage. By means of a human cartilage trauma model, we discovered that chondrocytes produced GDF-15 upon tissue injury, while antioxidative treatment attenuated GDF-15 secretion. In fact, GDF-15 expression was mediated by oxidative stress and subsequent activation of p53. As a transcriptional target of p53, GDF-15 was associated with chondrosenescence. However, GDF-15 induced pro-regenerative response in chondrocytes, characterized by enhanced proliferation as well as chondro- and cell protection after cartilage trauma. Overall, this study first describes GDF-15 as a senescence-associated but potentially pro-regenerative cytokine in the context of human PTOA.
| [1] |
B. Snoeker, A. Turkiewicz, K. Magnusson, et al., “Risk of Knee Osteoarthritis After Different Types of Knee Injuries in Young Adults: A Population-Based Cohort Study,” British Journal of Sports Medicine 54, no. 12 (2020): 725–730.
|
| [2] |
C. R. Maia, R. F. Annichino, E. de Azevedo, E. G. Machado, E. Marchi, and M. C. Castano-Betancourt, “Post-Traumatic Osteoarthritis: The Worst Associated Injuries and Differences in Patients' profile When Compared With Primary Osteoarthritis,” BMC Musculoskeletal Disorders [Electronic Resource] 24, no. 1 (2023): 568.
|
| [3] |
L. E. Bayliss, D. Culliford, A. P. Monk, et al., “The Effect of Patient Age at Intervention on Risk of Implant Revision After Total Replacement of the Hip or Knee: A Population-Based Cohort Study,” Lancet 389, no. 10077 (2017): 1424–1430.
|
| [4] |
A. C. Thomas, T. Hubbard-Turner, E. A. Wikstrom, and R. M. Palmieri-Smith, “Epidemiology of Posttraumatic Osteoarthritis,” Journal of Athletic Training 52, no. 6 (2017): 491–496.
|
| [5] |
Y. Song, Y. Cui, X. Zhang, et al., “Increased Serum Levels of MIC1/GDF15 Correlated With Bone Erosion in Spondyloarthritis: A Pilot Study,” Medicine 97, no. 51 (2018): e13733.
|
| [6] |
W. D. Xu, Q. Huang, C. Yang, R. Li, and A. F. Huang, “GDF-15: A Potential Biomarker and Therapeutic Target in Systemic Lupus Erythematosus,” Frontiers in Immunology 13 (2022): 926373.
|
| [7] |
D. A. Brown, J. Moore, H. Johnen, et al., “Serum Macrophage Inhibitory Cytokine 1 in Rheumatoid Arthritis: A Potential Marker of Erosive Joint Destruction,” Arthritis and Rheumatism 56, no. 3 (2007): 753–764.
|
| [8] |
J. Wischhusen, I. Melero, and W. H. Fridman, “Growth/Differentiation Factor-15 (GDF-15): From Biomarker to Novel Targetable Immune Checkpoint,” Frontiers in Immunology 11 (2020): 951.
|
| [9] |
F. E. Wiklund, A. M. Bennet, P. K. Magnusson, et al., “Macrophage Inhibitory Cytokine-1 (MIC-1/GDF15): A New Marker of all-Cause Mortality,” Aging Cell 9, no. 6 (2010): 1057–1064.
|
| [10] |
N. Arnold, M. Rehm, G. Buchele, et al., “Growth Differentiation Factor-15 as a Potent Predictor of Long-Term Mortality Among Subjects With Osteoarthritis,” Journal of Clinical Medicine 9, no. 10 (2020): 3107.
|
| [11] |
S. J. Baek and T. Eling, “Growth Differentiation Factor 15 (GDF15): A Survival Protein With Therapeutic Potential in Metabolic Diseases,” Pharmacology & Therapeutics 198 (2019): 46–58.
|
| [12] |
Y. Wan and J. Fu, “GDF15 as a Key Disease Target and Biomarker: Linking Chronic Lung Diseases and Ageing,” Molecular and Cellular Biochemistry 479, no. 3 (2023): 1–14.
|
| [13] |
O. H. Jeon, N. David, J. Campisi, and J. H. Elisseeff, “Senescent Cells and Osteoarthritis: A Painful Connection,” Journal of Clinical Investigation 128, no. 4 (2018): 1229–1237.
|
| [14] |
J. Riegger, A. Schoppa, L. Ruths, M. Haffner-Luntzer, and A. Ignatius, “Oxidative Stress as a Key Modulator of Cell Fate Decision in Osteoarthritis and Osteoporosis: A Narrative Review,” Cellular & Molecular Biology Letters 28, no. 1 (2023): 76.
|
| [15] |
J. Riegger and R. E. Brenner, “Pathomechanisms of Posttraumatic Osteoarthritis: Chondrocyte Behavior and Fate in a Precarious Environment,” International Journal of Molecular Sciences 21, no. 5 (2020): 1560.
|
| [16] |
B. Targonska-Stepniak and M. Majdan, “Cystatin C Concentration Is Correlated With Disease Activity in Rheumatoid Arthritis Patients,” Scandinavian Journal of Rheumatology 40, no. 5 (2011): 341–346.
|
| [17] |
V. Krenn, L. Morawietz, G. R. Burmester, et al., “Synovitis Score: Discrimination Between Chronic Low-Grade and High-Grade Synovitis,” Histopathology 49, no. 4 (2006): 358–364.
|
| [18] |
J. Riegger, M. Zimmermann, H. Joos, T. Kappe, and R. E. Brenner, “Hypothermia Promotes Cell-Protective and Chondroprotective Effects After Blunt Cartilage Trauma,” American Journal of Sports Medicine 46, no. 2 (2018): 420–430.
|
| [19] |
J. Riegger, H. Joos, H. G. Palm, et al., “Antioxidative Therapy in an Ex Vivo Human Cartilage Trauma-Model: Attenuation of Trauma-Induced Cell Loss and ECM-Destructive Enzymes by N-Acetyl Cysteine,” Osteoarthritis and Cartilage 24, no. 12 (2016): 2171–2180.
|
| [20] |
J. Riegger and R. E. Brenner, “Increase of Cell Surface Vimentin Is Associated With vimentin Network Disruption and Subsequent Stress-Induced Premature Senescence in Human Chondrocytes,” Elife 12 (2023): e91453.
|
| [21] |
J. Riegger, H. Joos, H. G. Palm, et al., “Striking a New Path in Reducing Cartilage Breakdown: Combination of Antioxidative Therapy and Chondroanabolic Stimulation After Blunt Cartilage Trauma,” Journal of Cellular and Molecular Medicine 22, no. 1 (2018): 77–88.
|
| [22] |
J. Riegger, F. Leucht, H. G. Palm, A. Ignatius, and R. E. Brenner, “Initial Harm Reduction by N-Acetylcysteine Alleviates Cartilage Degeneration After Blunt Single-Impact Cartilage Trauma In Vivo,” International Journal of Molecular Sciences 20, no. 12 (2019).
|
| [23] |
M. Osada, H. L. Park, M. J. Park, et al., “A p53-Type Response Element in the GDF15 Promoter Confers High Specificity for p53 Activation,” Biochemical and Biophysical Research Communications 354, no. 4 (2007): 913–918.
|
| [24] |
V. Kirsch, J. M. Ramge, A. Schoppa, A. Ignatius, and R. J. In, “Vitro Characterization of Doxorubicin-Mediated Stress-Induced Premature Senescence in Human Chondrocytes,” Cells 11, no. 7 (2022): 1106.
|
| [25] |
S. Maurer, V. Kirsch, L. Ruths, R. Brenner, and J. Riegger, “Senolytic Therapy Combining Dasatinib and Quercetin Restores the Chondrogenic Phenotype of human Osteoarthritic Chondrocytes by Promoting the Release of Pro-anabolic Mediators,” BioRxiv (2024).
|
| [26] |
D. S. Evans, D. Young, T. Tanaka, et al., “Proteomic Analysis of the Senescence-Associated Secretory Phenotype: GDF-15, IGFBP-2, and Cystatin-C Are Associated With Multiple Aging Traits,” Journals of Gerontology Series A, Biological Sciences and Medical Sciences 79, no. 3 (2024): glad265.
|
| [27] |
K. Kozyrska, G. Pilia, M. Vishwakarma, et al., “p53 Directs Leader Cell Behavior, Migration, and Clearance During Epithelial Repair,” Science 375, no. 6581 (2022): eabl8876.
|
| [28] |
R. Sarig, R. Rimmer, E. Bassat, et al., “Transient p53-Mediated Regenerative Senescence in the Injured Heart,” Circulation 139, no. 21 (2019): 2491–2494.
|
| [29] |
M. H. Yun, P. B. Gates, and J. P. Brockes, “Regulation of p53 Is Critical for Vertebrate Limb Regeneration,” PNAS 110, no. 43 (2013): 17392–17397.
|
| [30] |
Y. Liao, Y. Ren, X. Luo, et al., “Interleukin-6 Signaling Mediates Cartilage Degradation and Pain in Posttraumatic Osteoarthritis in a Sex-Specific Manner,” Science Signaling 15, no. 744 (2022): eabn7082.
|
| [31] |
A. I. Tsuchida, M. Beekhuizen, M. Rutgers, et al., “Interleukin-6 Is Elevated in Synovial Fluid of Patients With Focal Cartilage Defects and Stimulates Cartilage Matrix Production in an In Vitro Regeneration Model,” Arthritis Research & Therapy 14, no. 6 (2012): R262.
|
| [32] |
R. Shkhyan, C. Flynn, E. Lamoure, et al., “Inhibition of a Signaling Modality Within the gp130 Receptor Enhances Tissue Regeneration and Mitigates Osteoarthritis,” Science Translational Medicine 15, no. 688 (2023): eabq2395.
|
| [33] |
D. Gems and C. C. Kern, “Is “Cellular Senescence” a Misnomer?,” Geroscience 44, no. 5 (2022): 2461–2469.
|
| [34] |
M. E. Copp, M. C. Flanders, R. Gagliardi, et al., “The Combination of Mitogenic Stimulation and DNA Damage Induces Chondrocyte Senescence,” Osteoarthritis and Cartilage 29, no. 3 (2021): 402–412.
|
| [35] |
Y. W. He and C. S. He, “Association of Growth and Differentiation Factor 15 in Rheumatoid Arthritis,” Journal of Inflammation Research 15 (2022): 1173–1181.
|
| [36] |
F. Moschovaki-Filippidou, S. Steiger, G. Lorenz, et al., “Growth Differentiation Factor 15 Ameliorates Anti-Glomerular Basement Membrane Glomerulonephritis in Mice,” International Journal of Molecular Sciences 21, no. 19 (2020).
|
| [37] |
S. E. Segerer, L. Rieger, M. Kapp, et al., “MIC-1 (a Multifunctional Modulator of Dendritic Cell Phenotype and Function) Is Produced by Decidual Stromal Cells and Trophoblasts,” Human Reproduction 27, no. 1 (2012): 200–209.
|
| [38] |
O. Tanrikulu, M. A. Sariyildiz, I. Batmaz, et al., “Serum GDF-15 Level in Rheumatoid Arthritis: Relationship With Disease Activity and Subclinical Atherosclerosis,” Acta Reumatologica Portuguesa 42, no. 1 (2017): 66–72.
|
| [39] |
S. E. Mullican, X. Lin-Schmidt, C. N. Chin, et al., “GFRAL Is the Receptor for GDF15 and the Ligand Promotes Weight Loss in Mice and Nonhuman Primates,” Nature Medicine 23, no. 10 (2017): 1150–1157.
|
| [40] |
Z. Li, B. Wang, X. Wu, S. Y. Cheng, L. Paraoan, and J. Zhou, “Identification, Expression and Functional Characterization of the GRAL Gene,” Journal of Neurochemistry 95, no. 2 (2005): 361–376.
|
| [41] |
C. Laurens, A. Parmar, E. Murphy, et al., “Growth and Differentiation Factor 15 Is Secreted by Skeletal Muscle During Exercise and Promotes Lipolysis in Humans,” JCI Insight 5, no. 6 (2020): e131870.
|
| [42] |
Z. Zhao, J. Zhang, L. Yin, et al., “Upregulated GDF-15 Expression Facilitates Pancreatic Ductal Adenocarcinoma Progression Through Orphan Receptor GFRAL,” Aging (Albany NY) 12, no. 22 (2020): 22564–22581.
|
| [43] |
K. Buchholz, P. Antosik, D. Grzanka, et al., “Expression of the Body-Weight Signaling Players: GDF15, GFRAL and RET and Their Clinical Relevance in Gastric Cancer,” Journal of Cancer 12, no. 15 (2021): 4698–4709.
|
| [44] |
O. E. Olsen, A. Skjaervik, B. F. Stordal, A. Sundan, and T. Holien, “TGF-Beta Contamination of Purified Recombinant GDF15,” PLoS ONE 12, no. 11 (2017): e0187349.
|
| [45] |
S. Li, Y. M. Ma, P. S. Zheng, and P. Zhang, “GDF15 promotes the Proliferation of Cervical Cancer Cells by Phosphorylating AKT1 and Erk1/2 Through the Receptor ErbB2,” Journal of Experimental & Clinical Cancer Research 37, no. 1 (2018): 80.
|
| [46] |
K. W. Min, S. H. Lee, and S. J. Baek, “Moonlighting Proteins in Cancer,” Cancer Letters 370, no. 1 (2016): 108–116.
|
| [47] |
J. H. Kellgren and J. S. Lawrence, “Radiological Assessment of Osteo-Arthrosis,” Annals of the Rheumatic Diseases 16, no. 4 (1957): 494–502.
|
| [48] |
J. Riegger, M. Rehm, G. Buchele, et al., “Serum Cartilage Oligomeric Matrix Protein in Late-Stage Osteoarthritis: Association With Clinical Features, Renal Function, and Cardiovascular Biomarkers,” Journal of Clinical Medicine 9, no. 1 (2020): 268.
|
| [49] |
J. Riegger and R. E. Brenner, “Evidence of Necroptosis in Osteoarthritic Disease: Investigation of Blunt Mechanical Impact as Possible Trigger in Regulated Necrosis,” Cell Death & Disease 10, no. 10 (2019): 683.
|
RIGHTS & PERMISSIONS
2025 The Author(s). MedComm published by Sichuan International Medical Exchange & Promotion Association (SCIMEA) and John Wiley & Sons Australia, Ltd.
PDF
